Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunology & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPR65 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | GPR65 Full-Length ORF Lentivirus HEK293T packaging, CMV promoter, Puromycin selection. Sequence Verified. |
View GPR65 Products |
| Stable Cell Line | GPR65 Overexpression Cell Line (HEK293) High surface expression verified by Flow Cytometry. cAMP response validated. |
View GPR65 Products |
| Benchmark Antibody | Anti-GPR65 (Biosimilar Sequence) Recombinant positive control for assay development. Sequence Verified. |
View GPR65 Products |
| Validator | GPR65 siRNA Set (3 unique targets) For knockdown and specificity verification. Sequence Verified. |
View GPR65 Products |
| Related Target A | GPR68 (OGR1) Sister proton-sensing GPCR; critical for selectivity screening. |
View GPR68 Products |
| Related Target B | GPR132 (G2A) Proton-sensing GPCR family member; T-cell biology relevance. |
View GPR132 Products |
| Related Target C | GPR4 Proton-sensing GPCR family member for selectivity screening. |
View GPR4 Products |
| Related Target D | S1PR1 Sphingosine-1-phosphate receptor; psychosine pathway cross-talk. |
View S1PR1 Products |
| Related Target E | PD-L1 Synergistic target for tumor microenvironment immunotherapy. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| pH-Dependent Activation (pH 6.4-6.8 optimal) | Stable GPR65-expressing cell lines maintained in standardized buffers; cAMP assay ready with pH calibration controls |
| Gs-Coupled cAMP Accumulation | High-expression lentivirus (titer >10^8 TU/ml) ensuring robust signal-to-noise in HTRF/LANCE cAMP assays |
| Cross-species Preclinical Translation | Human/Mouse/Rat GPR65 ortholog lentiviruses available; sequence identity >85% for translational studies |
| Off-target Counter-screening (GPR68/GPR132/GPR4) | Proton-sensing GPCR panel available for selectivity validation (GPR65, GPR68, GPR132, GPR4) |
| Lack of Positive Controls | Sequence verified recombinant benchmark antibody included for assay standardization |
| False Positives / Baseline Controls | Validated siRNA included for specificity checks; Empty vector lentivirus controls available |
Live GPR65 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The proton-sensing GPCR GPR65 (TDAG8) represents an emerging frontier in immuno-oncology and autoimmune disease research. Unlike traditional GPCRs with peptide or small-molecule ligands, GPR65 responds to extracellular acidification (pH 6.4-6.8), making it a unique sensor for the tumor microenvironment (TME) and inflammatory sites. Current R&D focuses on understanding its role in macrophage polarization, T-cell regulation, and cancer cell metastasis. As first-generation immunotherapies face resistance, the next wave of R&D is highly focused on combining GPR65 modulators with immune checkpoint inhibitors to unlock refractory solid tumors. In autoimmune diseases (e.g., IBD), GPR65 is being evaluated as a potential target. First-generation chemical probes are entering preclinical validation, and the field anticipates a surge in selective antagonist programs targeting solid tumors and chronic inflammatory conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Academic Consortia, Early Biotech | Solid Tumors (Acidic TME), Autoimmune Diseases | cAMP Accumulation Assay using high-expression lentivirus cell lines; pH-controlled screening environments |
| Monoclonal Antibody | Preclinical Programs, Biotech | Autoimmune / IBD, Immuno-Oncology | Receptor binding assays (Flow Cytometry) using native conformation-preserving lentivirus lines; benchmark antibody control |
| Bispecific / Genetic Manipulation | Academic / Biotech | Refractory Cancers, Inflammation Models | Heterodimer validation; siRNA/shRNA tools; CRISPR-ready ORF lentivirus |
Key Genetic and Functional Evidence
A known missense variant in GPR65 (dbSNP:rs3742704) is associated with increased lysosomal pH and increased lipid droplets accumulation (UniProt VAR_022064). This genetic evidence underscores the receptor's role in cellular metabolism and pH homeostasis, providing a link to disease susceptibility and drug response variability.
Strategic Insights & TarMart Execution
Molecular Differentiation & Assay Strategy
1. pH Sensitivity Precision
- GPR65 is fully inactive at pH 7.0 and half-maximally activated at pH 6.4. Drugs must selectively block activation within this narrow pH window without affecting other receptors at physiological pH.
- Assay: pH gradient cAMP detection (HTRF/LANCE) using GPR65 stable cell lines, establishing dose-response curves over pH 6.0-7.5.
- TarMart: High-titer lentivirus (>10^8 TU/ml) ensures sufficient signal-to-noise (S/N >10) in transient/stable assays.
2. Family Selectivity
- Essential to differentiate GPR65 from GPR68, GPR132, and GPR4 to avoid off-target cardiovascular or metabolic effects.
- Assay: Ortholog cross-screening panel with at least 100-fold selectivity window.
- TarMart: Proton-sensing GPCR panel (GPR65, GPR68, GPR132, GPR4) in standardized HEK293 background with matched MOI.
3. Cellular Localization & Internalization
- Acidic environment may induce constitutive internalization; critical for antibody/ADC development.
- Assay: Flow cytometry surface staining + confocal internalization under varying pH.
- TarMart: N-terminal HA/Flag-tagged GPR65 lentivirus for surface expression quantification; siRNA for specificity.
4. Cross-Species Translation
- Human vs cynomolgus ~95% identity; human vs mouse ~85%.
- Assay: Species ortholog binding assay on isogenic cell lines.
- TarMart: Multi-species GPR65 ORF lentiviruses (Human, Cyno, Mouse, Rat), codon-optimized and sequence-verified.
5. Genetic Validation Tools
- siRNA knockdown + rescue experiments to confirm on-target specificity.
- TarMart: Three-target siRNA set (>80% knockdown efficiency) plus siRNA-resistant GPR65 mutant ORF.
Cross-Sell Strategy
- Bundle GPR68, GPR132, GPR4 lentiviruses as "Proton-Sensing GPCR Panel" for selectivity screening.
- Offer PD-L1 and S1PR1 related products for combined immunotherapy and pathway analysis.
Risk Mitigation
- No commercial benchmark antibody available for GPR65; TarMart provides sequence-verified biosimilar for assay control.
- For binding assays, avoid ECD-Fc protein and direct customers to cell-based binding using full-length lentivirus lines.